Ensysce Biosciences, Inc. (ENSC) Total liabilities 2020–2025
Ensysce Biosciences, Inc. (ENSC) total liabilities at each fiscal year-end, per SEC filings.
$4.6MFY2025 · since FY2020: $7.0M → $4.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $4.6M | +106.0% |
| FY2024 | $2.2M | -34.0% |
| FY2023 | $3.4M | -66.1% |
| FY2022 | $9.9M | -59.7% |
| FY2021 | $24.6M | +250.6% |
| FY2020 | $7.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ENSC financial trends
ENSC RevenueENSC Net incomeENSC Net marginENSC Gross profitENSC Gross marginENSC Operating incomeENSC Operating marginENSC Operating cash flowENSC Free cash flowENSC Capital expendituresENSC Return on equityENSC Stock buybacksENSC Dividends paidENSC Total assetsENSC Shareholders’ equityENSC overview →